Application Opening 30. September 2024 with announcement in the GPOH mailing list

Die German School of Pediatric Oncology and Hematology (kurz GsoPOH oder auch Winterschool) ist ein Fortbildungsangebot für Assistenzärtinnen und Assistenzärzte mit Interesse an der Kinderhämato- und -onkologie, sowie Fachärztinnen und Fachärzte in der Schwerpunktweiterbildung. In mehrere Module aufgeteilt ist es den Teilnehmer:innen über 4 Jahre möglich umfassende, auf die klinischen Aspekte zugeschnittene Vortragsreihen zu erleben und dabei in den direkten Kontakt mit den referierenden Studiengruppenleiter:innen zu kommen. Darüber hinaus fördern Gruppenarbeiten und Kurzvorträge den Austausch untereinander und bilden den Grundstein für weitere Aktivitäten innerhalb der GPOH

Das Angebot besteht seit 2015 und wurde von Prof. Dr. Dominik Schneider (Dortmund) und Prof. Dr. Angelika Eggert (Berlin) im Auftrag der GPOH ins Leben gerufen. Im Sommer 2022 ist das Programm in die mittlerweile dritte Runde gegangen (wegen Corona abweichend als „Summerschool“). Der aktuell laufende Zyklus besteht aus den Modulen:

• Modul I (Juni 2022): Leukämien & Lymphome

• Modul II (Januar 2023): Solide Tumoren

• Modul III (Januar 2024): Hämatologie, Hämostaseologie & Immunologie

• Modul IV (Januar 2025): ZNS Tumoren, Rhabdoidtumoren, Retinoblastome

Ein absolvieren der Module in der benannten Reihenfolge ist dabei nicht zwingend notwendig.

Die Veranstaltung wird möglich gemacht durch die großzügige Unterstützung der Deutschen Kinderkrebsstiftung.

More

The American Society of Hematology (ASH) Annual Meeting is a significant event in the field of hematology, gathering professionals, researchers, and practitioners to discuss the latest advancements in the study and treatment of blood disorders. The meeting features presentations on groundbreaking research, educational sessions, and opportunities for networking among attendees. It serves as a platform for sharing knowledge and innovations in hematology, covering topics like leukemia, lymphoma, anemia, and other blood-related conditions.

More

Welcome to the 9th International Tuebingen Symposium on Pediatric Solid Tumors „Innovations and Advances in Treatment of Rare Solid Tumors“. As in previous years we are delighted to welcome physicians and scientists from all over the world in Tuebingen.

Among solid tumors in children, pancreatic tumors, tumors in the ear, nose and throat area, endocrine tumors, NUT carcinoma, and DICER-1-driven tumors hold a particular status. For a long time, children and adolescents with rare tumors could not benefit from the successes of recent decades in the treatment of cancer. It is not only their rarity that emphasize the need for accumulation of knowledge through international networking and profound cooperation between the different specializations. Many of these tumors are so called adult type cancers, occurring rarely in children, however often presenting with different biology and clinical characteristics.

As it has become a tradition for our meeting, leading international experts on pediatric rare solid tumors (Oncology, Surgery, Radiology, Pathology, Radio-Oncology, and Biology) will be present at the 9th Tuebingen Symposium. Their contributions will ensure an outstanding scientific value of the event. Over the years the Tuebingen Symposium on Pediatric Solid Tumors has become recognized as a comprehensive and sustainable meeting, characterized not only by its scientific standard based on an interdisciplinary and international approach, but also by its character and the cordial atmosphere at the different social events. We are looking forward to an exciting meeting with fruitful discussions and new insights into the field of rare solid tumors.

Prof. Jörg Fuchs & Prof. Johannes Schulte & PD Dr. Ines Brecht & PD Dr. Andreas Schmidt
Congress Chairs

More

Die 98. Wissenschaftliche Tagung der GPOH findet am 22./23.11.2024 in Frankfurt, erneut im Tagungszentrum Dominikanerkloster statt.

More

Dear Friends and Colleagues,

The SIOPe BTG Training & Education (T&E) Group welcomes you to participate in the European Combined Neuro-Oncology Course, 3rd Year of the 2nd Cycle, in Lisbon, Portugal, between the 20th to the 22nd of November 2024.

The course is co-organized by the Young Investigators and Innovators (YII) Group of SIOPe BTG and provides an exceptional 3 day programme on diverse topics in Pediatric Neuro-Oncology, aiming to provide training to residents and young specialists across all disciplines.

This year’s programme includes sessions on spinal tumors, directions in medulloblastoma, innovative strategies and morbidities in CNS tumors, cancer predisposition and a round table on patient-centered care. There will be plenty of time for lively discussions during the presentation of difficult cases and practical workshops.

Additionally, this year will feature research talks for participants and a meeting with Young SIOPE to discuss the mentorship program. The best clinical case and talk by the participants will be awarded!

Lisbon is a beautiful and historic city with a dynamic energy. We will take the opportunity during the course to invite you to participate in a sportive activity and to enjoy the social events.

We warmly welcome everyone to Lisbon in 2024!

More

• 7th Swiss Oncology and Hematology Congress 2024, SOHC, 20. November 2024 – 22. November 2024, Basel, Switzerland

• SPOG/ SSPHO/ SGH Continuous Education Course: Hemoglobinopathy on 20. November 2024

• SSPHO sessions Young Investigator, Germ Cell Tumors, Fertility and LGG in AYA Patients on 21. November 2024

Striving for Individuality in Oncology and Hematology: A New Era of Personalized Treatment

In the ever-evolving landscape of oncology and hematology, the pursuit of individualized treatment has emerged as a beacon of hope and a testament to the power of personalized medicine. As experts convene for the seventh Swiss Oncology and Hematology congress, the theme "striving for individuality" underscores a paradigm shift that is transforming the lives of patients and redefining cancer care.

Historically, oncology has largely been characterized by a one-size-fits-all approach, where treatments were standardized based on cancer type and stage. However, the advent of personalized oncology has revolutionized this approach, leveraging advancements in genomics, molecular biology, and data analytics to tailor treatments to the unique genetic and molecular profiles of each patient’s tumor. As we gather to share knowledge and explore the frontiers of oncology and hematology, the commitment to striving for individuality in cancer treatment is more critical than ever. By embracing the principles of personalized medicine, we can offer hope to patients through treatments that are as unique as their own genetic makeup. This meeting is a sign of our collective dedication to advancing cancer care, ensuring that the promise of individualized treatment becomes a reality for all who face this formidable disease.

Do you also feel the lines above sound quite impressive but also somewhat pompous and pathetic? The reason may be that we generated the text using ChatGPT by prompting the system with ‘Write an editorial for a cancer experts meeting with the topic 'striving for individuality'. Include references to personalized oncology.’

We must confess we are impressed by the advances made both in the field of artificial intelligence and personalized therapy in the last years and we look very much forward to discussing these topics as well as the recent developments in oncology and hematology with you at the Swiss Oncology and Hematology Congress 2024. The SOHC is a unique opportunity to meet for personal interaction and a joint learning experience in an interdisciplinary and interprofessional environment. It provides both cutting-edge updates on current standards in oncology and hematology as well as a fertile ground to foster new ideas for clinical trials and new scientific projects. Individuality is not only found in personalized treatments but also in patients’ experiences, wishes and hopes. They shall also play an important role in this year’s SOHC.

In the name of the Swiss Society for Medical Oncology, the Swiss Society for Hematology, and the Swiss Group for Clinical Cancer Research, we welcome you to the SOHC 2024. We are honored by your participation and we wish you a rewarding and successful meeting. If you wish to read the whole, lengthy editorial of ChatGPT for the SOHC 2024, you will find the unedited text on the SOHC homepage (to the editorial).

Prof. Andreas Wicki, Congress President SOHC 2024
Prof. Jakob Passweg, President SOHC
Prof. Miklos Pless, Committee SOHC
M Sc Dominique Froidevaux, CEO SOHC

More

The Master Course of Pediatric Oncology offers a theoretical and applied curriculum at the advanced level for pediatric oncology fellows and early/mid-career pediatric oncologists. This 2-year course, consisting of 4 modules, is endorsed by SIOP. 

Starting with Module 4.2, we decided to extend the Master Course modules by half a day to allow more time for the interactive expert sessions (for the same fee). Each module now consists of two-and-a-half live days, which are accompanied by a comprehensive online program that covers key concepts and supports further extension of learning, which can be followed in a self-paced manner. The course is offered entirely in English. More information about the overall curriculum can be found at General Information.

The first Module of the 4th Master Course covers General aspects of childhood cancer. The topics vary from biology of cancer in children and an introduction to treatment modalities to psychosocial care and clinical research in pediatric oncology. The first Module also includes an introduction to Quality Improvement .
Module 2 covers all aspects of Hemato-oncology, whereas Modules 3 and 4 focus on Neuro-oncology and Solid tumors. Participants attending all modules will be challenged to design and implement a Quality Improvement project in their own working environment, with support of our faculty. Modules 2 until 4 will also include workshops focused on additional clinical and professional skills, like Workplace Teaching, Crew Resource Management, Moral Deliberation and Advanced Care Planning.

The first Module provides an excellent platform for Modules 2, 3 and 4, which are disease-oriented. We advise to attend all four modules, but it is possible to register for selected modules as well. It is also not required to follow all modules in sequence. Furthermore, you can enter mid-term and still complete the Master Course by attending modules of the next edition.

If you plan to attend the Live Days online, you should ensure adequate online connection. If the internet connection from your side is inadequate, this will influence the quality of the livestream.

The dates for the other modules are:
- Module 4.3 Neuro-oncology - April 23, 24 & 25, 2025 (NEW: 2.5 days)
- Module 4.4 Solid Tumors - November 12, 13 & 14, 2025 (NEW: 2.5 days)

CME accreditation has been requested for this course by the UEMS EACCME®. 

NOTES
1. Unfortunately, scholarships are no longer available for the 4th Master Course. The next opportunity to apply for a scholarship will be for the 5th Master Course in 2026-2027.
2. There is a reduced fee for participants from low- and middle-income countries. Check LMIC's overview to see which countries are covered.
3. There is a reduced fee for participants attending the live days online (hybrid version). Check the rates at the registration button.

More

OCTOBER 17-20, 2024 | HONOLULU, HAWAII

Experience 4 outstanding days of cutting-edge science, engaging debates and networking with world-renowned experts at SIOP 2024!

Advance your paediatric oncology career, connect with like-minded people, and contribute to a world where no child should die of cancer!

KEY DATES FOR YOUR CALENDAR

Early Bird Registration Deadline: July 17, 2024

October 17-20, 2024 – SIOP 2024

More